GlobeNewswire

Bergman & Beving AB: Bergman & Beving acquires Abtech

Share

Press release

Bergman & Beving acquires Abtech

Workplace Safety, a division within Bergman & Beving, has today acquired all shares in the British company group Abtech, consisting of Abtech Safety Ltd, Outreach Organisation Ltd and Outreach Rescue Medic Skills Ltd.

Abtech is a leading supplier of personal fall protection and rescue equipment in the United Kingdom that also provides advanced trainings and courses for the industrial sector and rescue specialists. Abtech was founded in 1991 and is headquartered in Flintshire, UK. The group has an annual revenue of approximately MGBP 3.7 with good profitability.

"Abtech’s strong position in the United Kingdom and deep product knowledge together with long experience within safety at heights, safety in confined spaces as well as safety on and around water, complements the business within Cresto Group”, says Fredrik Valentin, Head of Division Workplace Safety.

”We are very much looking forward to joining Bergman & Beving and Cresto Group and together drive development in safety at heights and rescue”, says the majority seller Ian Jones. “Abtech’s operations and culture fits well into Bergman & Beving's business model, where entrepreneurial companies can continue to develop with active support
from a strong owner.”

Closing is taking effect immediately and the acquisition is expected to bring a marginal positive contribution to Bergman & Beving's earnings per share during the current fiscal year.

Stockholm, 1 April 2021

Bergman & Beving AB (publ)

For further information, please contact:
Pontus Boman, President and CEO, phone +46 10 454 77 00
Peter Schön, CFO, phone +46 70 339 89 99

The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 CET on 1 April 2021.

Bergman & Beving owns and refines companies that develop and market strong brands for professional users in industry and construction, mainly in the Nordic region, the Baltic States and Poland. Bergman & Beving aims to enable successful product companies to take the next step and become leading brands in their categories. The Group currently has some 20 brands, about 1,000 employees and revenue of approximately SEK 4 billion. Bergman & Beving is listed on Nasdaq Stockholm. Read more on the company’s website: www.bergmanbeving.com.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Notification according to chapter 9, section 10 of the Securities Market Act: Bolero Holdings SARL ownership in Suominen decreases to below 5 percent16.4.2021 15:30:00 CEST | Press release

Suominen Corporation, stock exchange release on April 16, 2021 at 4.30 p.m. (EET). Suominen Corporation has on April 16, 2021 received a notification referred to in Chapter 9, Section 5 and 6 of the Securities Market Act. According to the notification, the shareholding of Bolero Holdings SARL in Suominen Corporation has fallen below the 5% flagging threshold. Total positions of person subject to the notification obligation: % of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of the issuerResulting situation on the date on which threshold was crossed or reachedBelow 5%n/aBelow 5%58,259,219Position of previous notification (if applicable)5.81%n/a5.81% Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rightsClass/type of sharesNumber of shares and voting rights% of shares and votin

Correction: REGARDING DRAFT ALTERNATIVE RESOLUTION SUBMITTED TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.4.2021 14:49:32 CEST | Press release

Correction: the number of shares indicated – 380.396.585 and declared dividends per share – 0,0198 EUR. On 15 April 2021 AB “Klaipėdos nafta” (hereinafter – Company) received a proposal from the Ministry of Energy of the Republic of Lithuania (hereinafter referred to as the Shareholder), that executes the rights of the Shareholder – the Republic of Lithuania that owns 275 687 444 ordinary registered shares, making 72,45 per cent of the total amount of the Company’s shares, on an alternative draft resolution of the issue on the agenda of the ordinary registered meeting of shareholders of the Company to be convened on 30 April 2021. Following paragraphs 3, 4 and 5 of Article 25 of the Law on Companies of the Republic of Lithuania, the Shareholder as the person exercising the right to propose draft resolutions of the Company’s General Meeting, holding shares that grant at least 1/20 of all the votes, proposes to approve the following draft resolution of the fourth item on the agenda of th

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)16.4.2021 14:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 16 April 2021 at 3:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 April 2021 above five (5) per cent of Sampo plc’s total voting rights. In addition, the disclosure obligation arose due to the number of Sampo A shares owned directly or indirectly by BlackRock, Inc. and its funds increasing above 5 per cent. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions

CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 1016.4.2021 12:45:00 CEST | Press release

Allentown, April 16, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 10 ALLENTOWN, PA, April 16, 2021 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its first quarter 2021 results after the market closes on Monday, May 10, 2021. In conjunction with the news release, management will host a conference call on Tuesday, May 11, at 9:00 a.m. Eastern Time. The conference call numbers are 800-774-6070 or 630-691-2753 and the passcode for both is 7265208#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website (www.crossamericapartners.com). To listen to the audio webcast, go to https://caplp.gcs-web.com/webcasts-presentations https://caplp.gcs-web.com/webcasts-presentations. A

Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD16.4.2021 11:00:00 CEST | Press release

Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression. Oladele Adebogun M.D. said, “I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the number of pat

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS16.4.2021 10:08:23 CEST | Press release

Auction date2021-04-16Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 400Volume offered, SEK mln4,000Volume bought, SEK mln750Number of bids12Number of accepted bids3Average yield0.367 %Lowest accepted yield0.367 %Highest yield0.368 %% accepted at lowest yield 65.00 Auction date2021-04-16Loan1053Coupon3.50 %ISIN-codeSE0002829192Maturity2039-03-30Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,400Volume bought, SEK mln500Number of bids5Number of accepted bids2Average yield0.696 %Lowest accepted yield0.693 %Highest yield0.698 %% accepted at lowest yield 100.00 Auction date2021-04-16LoanREGS Kingdom of SwedenCoupon0.125 %ISIN-codeXS2226974504Maturity2030-09-09Tendered volume, SEK mln250 +/- 250Volume offered, SEK mln600Volume bought, SEK mln250Number of bids6Number of accepted bids3Average yield0.287 %Lowest accepted yield0.281 %Highest yield0.291 %% accepted at lowest yield 50.00

Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®16.4.2021 09:00:00 CEST | Press release

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy. The trial is originated by the principal investigator of the trial, Dr Michael Häggman, Associate Professor at the Department of Surgical Sciences in Urology, Uppsala University Hospital. The study is planned to start in mid of this year and it will enroll 10- 15 patients to be treated with NZ-DTX prior to planned surgery. “The NanoZolid technology is suitable to combine with the MRI/TRUS injection technique for a high precision intratumoral delivery of NZ-DTX Depot. Treating patients prior to removal of the prostate gland will provide exhaustive information with regards to local effects in the tumor and surrounding tissue”, commented Dr Michael Häggman. “We are very pleased